252 related articles for article (PubMed ID: 28543693)
1. Somatic driver mutations in melanoma.
Reddy BY; Miller DM; Tsao H
Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
[TBL] [Abstract][Full Text] [Related]
2. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
3. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
5. Frequencies of KIT and GNAQ mutations in acral melanoma.
Puntervoll HE; Molven A; Akslen LA
J Cutan Pathol; 2014 Nov; 41(11):893-4. PubMed ID: 25363280
[No Abstract] [Full Text] [Related]
6. Melanoma.
Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
[TBL] [Abstract][Full Text] [Related]
7. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
8. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
9. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
Royer-Bertrand B; Torsello M; Rimoldi D; El Zaoui I; Cisarova K; Pescini-Gobert R; Raynaud F; Zografos L; Schalenbourg A; Speiser D; Nicolas M; Vallat L; Klein R; Leyvraz S; Ciriello G; Riggi N; Moulin AP; Rivolta C
Am J Hum Genet; 2016 Nov; 99(5):1190-1198. PubMed ID: 27745836
[TBL] [Abstract][Full Text] [Related]
11. Mutational Profile of Driver Genes in Brazilian Melanomas.
Vicente ALSA; Crovador CS; Macedo G; Scapulatempo-Neto C; Reis RM; Vazquez VL
J Glob Oncol; 2019 Nov; 5():1-14. PubMed ID: 31756131
[TBL] [Abstract][Full Text] [Related]
12. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
13. Structural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma.
Djulbegovic MB; Uversky VN; Harbour JW; Galor A; Karp CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34681018
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
15. Exome sequencing reveals the likely involvement of SOX10 in uveal melanoma.
Das D; Kaur I; Ali MJ; Biswas NK; Das S; Kumar S; Honavar SG; Maitra A; Chakrabarti S; Majumder PP
Optom Vis Sci; 2014 Jul; 91(7):e185-92. PubMed ID: 24927141
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and mutational analyses of melanocytic tumors.
Gerami P; Busam KJ
Dermatol Clin; 2012 Oct; 30(4):555-66, v. PubMed ID: 23021045
[TBL] [Abstract][Full Text] [Related]
17. GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?
Field MG; Harbour JW
Cancer Cell; 2014 Jun; 25(6):714-5. PubMed ID: 24937456
[TBL] [Abstract][Full Text] [Related]
18. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Henary H; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R
Ann Oncol; 2013 Aug; 24(8):2158-65. PubMed ID: 23576709
[TBL] [Abstract][Full Text] [Related]
19. Mutational status of naevus-associated melanomas.
Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
[TBL] [Abstract][Full Text] [Related]
20. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]